Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Sci Monit. 2006 Nov;12(11):CR467-70.

Accelerated versus classical hepatitis B virus vaccination programs in healthcare workers accelerated vs. classical HBV vaccination.

Author information

1
Department of Internal Medicine Division of Oncology, Ataturk Training and Research Hospital, Izmir, Turkey.

Abstract

BACKGROUND:

The aim of this study was to compare the efficacy of a standard hepatitis B virus vaccination program (day 0-30-60) with an accelerated vaccination program (day 0-10-21) in healthy healthcare workers.

MATERIAL/METHODS:

Participants were randomly assigned to a classical (group 1, days 0, 30, and 60) or an accelerated vaccination program (group 2, days 0, 10, and 21). The vaccine used was 20 pg recombinant hepatitis B vaccine (recombinant hepatitis B vaccine derived from yeast cells, Engerix B, Smith Cline Beachum). HBV markers were re-examined for the emergence of anti-HBsAg and also to detect the development of a possible acute HBV infection one, two, and three months after the last dose of vaccine. Anti-HBsAg titers >10 mIU/l were accepted as protective.

RESULTS:

The seroprotection rates were similar one, two, and three months after the last dose of vaccine in both groups. Anti-HBsAg titers in group 1 were higher than in group 2 two and three months after the last dose of vaccination (p<0.05).

CONCLUSIONS:

Our data indicate that the accelerated HBV vaccination program was as effective as the classical vaccination program.

PMID:
17072271
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for International Scientific Literature, Ltd.
    Loading ...
    Support Center